a few people working at a table

Press Releases

Ladenburg Thalmann Acts as Sole Book-Running Manager for Salarius Pharmaceuticals, Inc. (SLRX) in its $23 Million Follow-On Offering

Transaction Information Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) announced the closing of its previously...

Ladenburg Thalmann Acts as Co-Manager for Cyclacel Pharmaceuticals, Inc. (CYCC) in its $14.5 Million Follow-On Offering

Transaction Information Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) announced the closing of its previously...

Ladenburg Thalmann Acts as Sole Book-Running Manager for CHF Solutions, Inc. (CHFS) in its $20.9 Million Follow-On Offering

Transaction Information CHF Solutions, Inc. (NASDAQ: CHFS) announced the closing of its previously announced...

Ladenburg Thalmann Acts as Co-Placement Agent for 4D pharma plc (LBPS) in its $25 Million Private Placement

4D pharma plc (NASDAQ: LBPS), announced the completion of its private placement in connection with its merger with...

Ladenburg Thalmann Acts as Joint Book-Running Manager for Windtree Therapeutics, Inc. (WINT) in its $30.0 Million Follow-On Offering

Transaction Information Windtree Therapeutics, Inc. (NASDAQ: WINT) announced the closing of its previously announced...

Ladenburg Thalmann Acts as Lead Manager for Evaxion Biotech A/S (EVAX) in its $30 Million Initial Public Offering

Transaction Information Evaxion Biotech A/S (NASDAQ: EVAX) announced the closing of its initial public offering...

Ladenburg Thalmann Acts as Sole Book-Runner for Helius Medical Technologies, Inc. (HSDT) in its $11 Million Follow-On Offering Priced At Market

Transaction Information Helius Medical Technologies, Inc. (Nasdaq: HSDT) (TSX: HSM) announced the closing of an...

Ladenburg Thalmann Acts as Co-Manager for Krystal Biotech, Inc. (KRYS) in its $143 Million Follow-On Offering

Transaction Information Krystal Biotech, Inc. (NASDAQ: KRYS) announced that it has priced the previously...

Ladenburg Thalmann Acts as Sole Book-Runner for Hancock Jaffe Laboratories, Inc. (HJLI) in its Upsized $41 Million Follow-On Offering

Transaction Information Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI) announced that it has successfully...